Aegis Therapeutics, LLC Awarded Patent for Absorption-Enhancing Self-Assembling Thixotropic Aqueous Hydrogels
SAN DIEGO, CA--(Marketwire - December 11, 2012) -
Highlighted Links |
http://aegisthera.com |
The company is seeking licensees for prescription and OTC applications of the Aegis Hydrogels™.
About Aegis Therapeutics
Aegis Therapeutics LLC is a drug delivery technology company commercializing its patented drug delivery and drug formulation technologies through product-specific licenses. Our Intravail® drug delivery technology enables the non-invasive delivery of a broad range of protein, peptide and non-peptide drugs that can currently only be administered by injection, via the oral, buccal, and intranasal administration routes, and with high bioavailability. Our ProTek® excipients stabilize, prevent aggregation, and reduce unwanted immunogenicity of protein and peptide therapeutics while avoiding the oxidative damage caused by polysorbate surfactants currently found in most protein injectable drugs.
For more information about Aegis, please visit: http://www.aegisthera.com.
Contact:
Ralph Barry
Chief Business Officer
Aegis Therapeutics LLC
1-858-618-1400 Ext. 102
Email: Email Contact